

Comparative Effectiveness of Combined Favipiravir and Oseltamivir Monotherapy in Critically Ill Patients With

Journal of Infectious Diseases

221, 1688-1698

DOI: [10.1093/infdis/jiz656](https://doi.org/10.1093/infdis/jiz656)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <i>Frontiers in Medicine</i> , 2020, 7, 546.	1.2	5
2	Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravir. <i>Antiviral Research</i> , 2020, 184, 104952.	1.9	7
3	The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. <i>Virology</i> , 2020, 551, 1-9.	1.1	179
4	Efficacy of early prone or lateral positioning in patients with severe COVID-19: a single-center prospective cohort. <i>Precision Clinical Medicine</i> , 2020, 3, 260-271.	1.3	10
5	Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 2211-2223.	1.3	10
6	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
7	Favipiravir use for SARS CoV-2 infection. <i>Pharmacological Reports</i> , 2020, 72, 1542-1552.	1.5	18
8	A web visualization tool using T cell subsets as the predictor to evaluate COVID-19 patient's severity. <i>PLoS ONE</i> , 2020, 15, e0239695.	1.1	6
9	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2020, 11, 361.	2.4	227
10	Oseltamivir in the treatment of severe type-A H1N1 flu and autoregressive integrated moving average mathematical model analysis of epidemiology. <i>Results in Physics</i> , 2020, 19, 103617.	2.0	0
11	Old and re-purposed drugs for the treatment of COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 843-847.	2.0	49
12	A Precision Medicine Approach to SARS-CoV-2 Pandemic Management. <i>Current Treatment Options in Allergy</i> , 2020, 7, 422-440.	0.9	25
13	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. <i>Pharmacological Research</i> , 2020, 158, 104899.	3.1	175
14	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6
15	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. <i>Pharmacological Research</i> , 2020, 160, 105036.	3.1	29
16	Influenza Virus in Community-Acquired Pneumonia: Current Understanding and Knowledge Gaps. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 555-567.	0.8	3
17	A Trial of Lopinavirâ€“Ritonavir in Adults Hospitalized with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1787-1799.	13.9	4,209
18	The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2381-2383.	1.3	2

#	ARTICLE	IF	CITATIONS
19	A review of the safety of favipiravir " a potential treatment in the COVID-19 pandemic?. Journal of Virus Eradication, 2020, 6, 45-51.	0.3	183
20	Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. , 2020, 209, 107512.		363
21	Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends, 2020, 14, 69-71.	1.1	852
22	An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1-11.	2.0	278
23	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clinical Immunology, 2020, 215, 108409.	1.4	217
24	The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic Journal of Cardiology, 2020, 61, 42-45.	0.4	114
25	Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology and Infection, 2020, 53, 436-443.	1.5	393
26	Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. Journal of Medical Virology, 2020, 92, 1922-1931.	2.5	18
27	Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises. Stem Cell Reviews and Reports, 2021, 17, 163-175.	1.7	59
28	Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038687.	2.9	45
29	Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, 2021, 102, 501-508.	1.5	293
30	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	3.2	44
31	Transfusion reactions associated with <scp>COVID</scp>"19 convalescent plasma therapy for <scp>SARS"CoV</scp>"2. Transfusion, 2021, 61, 78-93.	0.8	17
32	Favipiravir in Therapy of Viral Infections. Journal of Clinical Medicine, 2021, 10, 273.	1.0	39
33	Management of Influenza Virus Infections (Orthomyxoviridae). , 2021, , 160-174.		0
34	Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials, 2021, 22, 71.	0.7	24
35	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
36	Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Annals of Medicine, 2021, 53, 391-401.	1.5	28

#	ARTICLE	IF	CITATIONS
37	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kininâ€“Kallikrein System in Severe COVID-19. <i>Viruses</i> , 2021, 13, 309.	1.5	35
38	The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study. <i>Aging</i> , 2021, 13, 7020-7034.	1.4	62
39	Investigation of the disease process and drug combinations in patients with suspected/confirmed COVIDâ€“19 using favipiravir. <i>International Journal of Clinical Practice</i> , 2021, 75, e14167.	0.8	3
40	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 52-66.	0.6	5
41	Obesity and Critical Illness in COVIDâ€“19: Respiratory Pathophysiology. <i>Obesity</i> , 2021, 29, 870-878.	1.5	23
42	Preparing for the 2020â€“2021 influenza season. <i>Pediatric Transplantation</i> , 2021, 25, e14025.	0.5	4
43	A Systematic Review on Various Therapeutic Options for Coronavirus Outbreak. <i>Journal of Drug Delivery and Therapeutics</i> , 2021, 11, 185-194.	0.2	0
44	Risk Factors of Viral RNAemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19. <i>Chest</i> , 2021, 159, 1382-1386.	0.4	12
45	COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1170-1184.	0.9	13
46	Drug combination therapy for emerging viral diseases. <i>Drug Discovery Today</i> , 2021, 26, 2367-2376.	3.2	65
47	Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 857-863.	0.8	2
48	Pharmacovigilance Activities in the Treatment of COVID-19. <i>Hacettepe University Journal of the Faculty of Pharmacy</i> , 2021, 41, 93-101.	0.0	0
49	Coalescence of co-infection and antimicrobial resistance with SARS-CoV-2 infection: The blues of post-COVID-19 world. <i>Case Studies in Chemical and Environmental Engineering</i> , 2021, 3, 100093.	2.9	11
50	An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. <i>Antibiotics</i> , 2021, 10, 690.	1.5	29
51	SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions. <i>Coronaviruses</i> , 2021, 2, .	0.2	2
52	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.3	1
53	Heterocyclic compounds as antiviral drugs: Synthesis, structureâ€“activity relationship and traditional applications. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 2226-2260.	1.4	15
54	Variation in COVID-19 disease severity at hospital admission over time and across hospitals. <i>Medicine (United States)</i> , 2021, 100, e27265.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isriv Antiviral group. <i>Antiviral Research</i> , 2021, 194, 105158.	1.9	24
56	The COVID-19 puzzle: a global nightmare. <i>Environment, Development and Sustainability</i> , 2021, 23, 12710-12737.	2.7	11
62	Therapeutic strategies for critically ill patients with COVID-19. <i>Annals of Intensive Care</i> , 2020, 10, 45.	2.2	100
63	A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. <i>Medical Science Monitor</i> , 2020, 26, e926651.	0.5	16
64	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0243705.	1.1	62
65	The 2019â€“2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. <i>Journal of Global Infectious Diseases</i> , 2020, 12, 47.	0.2	270
67	Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?. <i>Engineering</i> , 2022, 19, 139-152.	3.2	20
69	Influenza Virus Infection and Transplantation. <i>Transplantation</i> , 2021, 105, 968-978.	0.5	7
70	Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009997.	1.3	24
71	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110630.	1.1	7
72	Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection. <i>Viruses</i> , 2022, 14, 111.	1.5	6
73	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204521.	1.4	6
74	Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children. <i>Frontiers in Pharmacology</i> , 2022, 13, 849545.	1.6	2
75	Management of Severe Influenza. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 771-787.	0.8	2
76	Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza: study protocol for a randomized parallel placebo-controlled double-blind multicenter trial. <i>Trials</i> , 2021, 22, 955.	0.7	4
77	Influenza Virus Entry inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 123-135.	0.8	1
78	Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Infectious Diseases</i> , 2022, 226, 1790-1799.	1.9	16
79	Preclinical and clinical developments for combination treatment of influenza. <i>PLoS Pathogens</i> , 2022, 18, e1010481.	2.1	13

#	ARTICLE	IF	CITATIONS
80	Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. <i>Antibiotics</i> , 2022, 11, 805.	1.5	10
81	Win ratio approach for analyzing composite <sc>timeâ€œâ€œevent</sc> endpoint with opposite treatment effects in its components. <i>Pharmaceutical Statistics</i> , 0, .	0.7	2
84	Clinical significance and role of coinfections with respiratory pathogens among individuals with confirmed severe acute respiratory syndrome coronavirus-2 infection. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
85	Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. <i>Antiviral Research</i> , 2022, 208, 105430.	1.9	41
86	Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial. <i>PLoS ONE</i> , 2022, 17, e0277790.	1.1	3
87	Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 415-424.	5.2	16
88	Influenza antivirals and their role in pandemic preparedness. <i>Antiviral Research</i> , 2023, 210, 105499.	1.9	17
89	Antiviral Approaches against Influenza Virus. <i>Clinical Microbiology Reviews</i> , 2023, 36, .	5.7	18
90	Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. <i>Microorganisms</i> , 2023, 11, 183.	1.6	11
91	Favipiravirâ€™Tautomeric and Complexation Properties in Solution. <i>Pharmaceuticals</i> , 2023, 16, 45.	1.7	5
92	Antiviral therapies for influenza. <i>Current Opinion in Infectious Diseases</i> , 2023, 36, 124-131.	1.3	4
93	Synthesis, crystal structure and DFT study of ethyl (3aR,7R,7aR)-2,2-dimethyl-7-((methylsulfonyl)oxy)-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-carboxylate. <i>Journal of Molecular Structure</i> , 2023, 1282, 135214.	1.8	1
94	Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. <i>Molecules</i> , 2023, 28, 2332.	1.7	6
95	Penggunaan Antivirus untuk COVID-19. , 2021, 48, 419-422.		0
101	The Clinical Practices and Post-Treatment Care for COVID-19 Patients With Heart Complications. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 167-189.	0.1	0